Safety, Feasibility and Technical Considerations from a Prospective, Observational Study-CIREL: Irinotecan-TACE for CRLM in 152 Patients

CIREL, a prospective, Europe-wide, observational study aimed to assess the real-world feasibility and tolerability of irinotecan-based transarterial chemoembolization (LP-irinotecan TACE) for unresectable colorectal cancer liver metastases with regard to the treatment plan and adverse events (AEs)....

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-10, Vol.11 (20), p.6178
Main Authors: Helmberger, Thomas, Lucatelli, Pierleone, Pereira, Philippe L, Gjoreski, Aleksandar, Jovanoska, Ivona, Bansaghi, Zoltan, Spiliopoulos, Stavros, Carchesio, Francesca, Arnold, Dirk, Baierl, Andreas, Zeka, Bleranda, Kaufmann, Nathalie C, Taieb, Julien, Iezzi, Roberto
Format: Article
Language:English
Subjects:
Ablation
Cancer therapies
Chemotherapy
Chi-square test
Clinical medicine
Colorectal cancer
Drug dosages
Laboratories
Liver
Metastasis
Observational studies
Patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CIREL, a prospective, Europe-wide, observational study aimed to assess the real-world feasibility and tolerability of irinotecan-based transarterial chemoembolization (LP-irinotecan TACE) for unresectable colorectal cancer liver metastases with regard to the treatment plan and adverse events (AEs). CIREL enrolled 152 eligible patients (≥18 years) with liver-only or dominant metastases treated with LP-irinotecan TACE following a multidisciplinary tumor board decision. Data were prospectively collected for baseline, the number of planned and performed sessions, and technical information and safety according to CTCAE 4.03/5.0. Results from 351 analyzed treatment sessions showed technical success for 99% of sessions, and 121 patients (79%) completed all planned sessions. Further, 60% of sessions were performed using opioids, 4% intra-arterial anesthetics, and 25% both. Additionally, 60% of patients experienced at least one peri-interventional AE of any grade; 8% of grade 3−4. Occurrence of AEs was related to larger liver-involvement (p < 0.001), bi-lobar disease (p = 0.002), and larger beads (p < 0.001). Using corticosteroids together with antiemetics showed reduced and lower grade vomiting (p = 0.01). LP-irinotecan TACE was tolerated well and had a high proportion of completed treatment plans. This minimally invasive locoregional treatment can be used together with concomitant systemic therapy or ablation.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11206178